Wall Street analyst estimates for AIM ImmunoTech Inc. (AIM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-16 | $-0.09 | ||
| 2026-08-07 | $-0.43 | $-0.17 | -152.9% |
| 2026-05-15 | $-0.69 | $-1.08 | +36.1% |
| 2026-03-27 | $-1.36 | $-0.94 | -44.7% |
| 2025-11-17 | $-1.57 | $-0.97 | -61.0% |
| 2025-08-14 | $-3.68 | $-8.00 | +54.0% |
| 2025-05-14 | $-5.00 | $-8.00 | +37.5% |
| 2025-03-27 | $-10.00 | $-9.00 | -11.1% |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.40 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92000 | $437000 | $367000 | $140000 | $163000 | $135000 | $141000 | $202000 | $170000 | $88000 |
| Cost of Revenue | $1.1M | $1.2M | $884000 | $893000 | $806000 | $850000 | 0 | $42000 | $31000 | $338000 |
| Gross Profit | -$1.0M | -$746000 | -$517000 | -$753000 | -$643000 | -$715000 | $141000 | $160000 | $139000 | -$250000 |
| Research & Development | $5.1M | $4.1M | $4.8M | $4.7M | $5.7M | $7.7M | $7.0M | $10.9M | $6.2M | $3.9M |
| Selling, General & Admin | $7.7M | $6.6M | $6.2M | $7.0M | $8.7M | $8.7M | $13.1M | $21.1M | $13.7M | $7.7M |
| Operating Expenses | $12.8M | $10.7M | $11.0M | $11.7M | $14.5M | $18.1M | $20.1M | $32.1M | $19.9M | $10.3M |
| Operating Income | -$13.8M | -$11.4M | -$11.5M | -$12.4M | -$15.2M | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$10.5M |
| EBITDA | -$6.3M | -$7.1M | -$8.4M | -$8.1M | -$13.0M | -$18.3M | -$19.2M | -$28.7M | -$16.5M | -$12.9M |
| Interest Expense | 0 | $139000 | $502000 | $427000 | $672000 | $67000 | 0 | 0 | $585000 | $812000 |
| Pre-tax Income | -$7.5M | -$8.3M | -$9.8M | -$9.4M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Income Tax | 0 | 0 | $2.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$7.5M | -$8.3M | -$9.8M | -$9.4M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| EPS | $-543.05 | $-463.19 | $-355.19 | $-93.71 | $-16.41 | $-14.67 | $-14.69 | $-21.64 | $-11.22 | $-8.62 |
| EPS (Diluted) | $-543.05 | $-463.19 | $-355.19 | $-93.71 | $-16.41 | $-14.67 | $-14.69 | $-21.64 | $-11.22 | $-8.62 |
| Shares Outstanding (Diluted) | $13669 | $17967 | $27689 | $100429 | $877903 | $1.3M | $1.3M | $1.3M | $1.5M | $1.6M |
Price
| Price | $0.21 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Related companies: CANF · ENSC · KALA · KTTA · OGEN · QNRX · SNGX
Explore sector: Healthcare · Biotechnology
More sections of AIM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks